An Open-label, Multicenter Phase Ib Study of the Safety and Tolerablility of Atezolizumab (ANTIPD-L1 Antibody) Administered in Combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
This study is closed
Gulam Manji, MD, PhD
|Have you been diagnosed with gastric cancer or metastatic pancreatic cancer?